Generic Name and Formulations:
Bacitracin 50,000units/vial; pwd for IM inj after reconstitution.
X-GEN Pharmaceuticals, Inc
Indications for BACIIM:
Susceptible infections due to staphylococci, including pneumonia and empyema in infants.
Give by IM inj into upper outer quadrant of buttocks. Infants: <2.5kg: 900units/kg per day in 2–3 divided doses; >2.5kg: 1,000units/kg per day in 2–3 divided doses.
Renal impairment. Monitor renal function before and daily during therapy; discontinue if renal toxicity occurs. Ensure adequate hydration.
Avoid other nephrotoxic drugs (eg, aminoglycosides, polymyxin B, colistin).
Nephrotoxicity (eg, albuminuria, azotemia, cylinduria), nausea, vomiting, rash, inj site pain.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|